Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paritaprevir and Ombitasvir with pegIFN/RBV in HCV Patients with Prior DAA Failure
NCT01609933Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2012
- Primary completion
- May 2017
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label trial of paritaprevir and ombitasvir in hepatitis C (HCV), sponsored by AbbVie Inc. Started Dec 2012; status: completed.
02
Drugs
paritaprevirombitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01609933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609933.